Amgen expands cardiovascular portfolio with Dezima acquisition
Friday, September 18, 2015 - 08:10
in Health & Medicine
Amgen’s $300 million purchase of Dutch biotech gives the company the potential to offer more varied treatment options to lower cholesterol